Phase I trial of the selective mitochondrial toxin MKT 077 in chemo- resistant solid tumours

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 923-927

  Propper, D J ^a   Braybrooke, J P ^a   Taylor, D J ^b   Lodi, R ^b   Styles, P ^b   Cramer, J A ^c   Collins, W C J ^c   Levitt, N C ^a   Talbot, D C ^a   Ganesan, T S ^a   Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Mitochondrial toxin; MKT 077; Phase I trial

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MITOCHONDRIAL MYOPATHY; MUSCLE MITOCHONDRION; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SKELETAL MUSCLE; SOLID TUMOR;

EID: 0032834594     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008336904585     Document Type: Article

References (15)

1. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988; 4: 155-81.
2. Summerhayes IC, Lampidis TJ, Bernai SD et al. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 1982; 79: 5292-6.
3. Lampidis TJ, Bernai SD, Summerhayes IC, Chen LB. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res 1983; 43: 716-20.
4. Koya K, Li Y, Wang H et al. MKT077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 1996; 56: 538-43.
5. Chiba Y, Kubota T, Watanabe M et al. MKT077, localized lipophilic cation - antitumor-activity against human tumor xenografts serially transplanted into nude-mice. Anticancer Res 1998; 18: 1047-52.
6. Weisberg EL, Koya K, Modica-Napolitano J et al. In vivo administration of MKT-077 causes partial yet reversible impairment of mitochondrial function. Cancer Res 1996; 56: 551-5.
7. Taylor DJ, Radda GK (eds). Non-Invasive Methods, Volume 17. San Francisco: Academic Press 1994.
8. Arnold DL, Taylor DJ, Radda GK. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol 1985; 18: 189-96.
9. 31P NMR. Magn Reson Med 1984; 1: 307-15.
10. 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise. NMR Biomed 1993; 6: 302-10.
11. Cramer JA, O'Neill DW, Xu G, Eder JP. Single-dose pharmacokinetics of SDZ MKT077, a rhodacyanine derivative for the treatment of solid tumors. Pharmaceut Res V 1997; 14: S506.
12. Britten CD, Rowinsky EK, Baker SD et al. A phase 1 and pharmacokinetic (PK) study of the rhodacyanine dye analog MKT077. Am Soc Clin Oncol Annual Meet 1998; 17: A886.
13. 31P magnetic resonance spectroscopic study. Br J Cancer 1995; 72: 998-1003.
14. 31P magnetic resonance spectroscopy. Cancer Res 1993; 53: 5649-53.
15. Thompson CH, Irish A, Kemp GJ et al. Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. Clin Nephrol 1996; 45: 386-9.